NASDAQ$ASTH

Astrana Health Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Announced fourth quarter and year-end results, demonstrating growth in revenue and net income.

Apollo Medical Holdings reported a 10% increase in total revenue to $195.1 million and a 37% increase in net income to $13.8 million for the fourth quarter of 2021. The company's EPS - diluted increased by 11% to $0.30 per share.

  • Total revenue increased by 10% year-over-year to $195.1 million.
  • Net income attributable to ApolloMed increased by 37% year-over-year to $13.8 million.
  • Earnings per share - diluted increased by 11% year-over-year to $0.30.
  • Acquisition of Jade Health expected to close by the end of the second quarter of 2022.

Headline financials

Total Revenue

$23.3M

Previous: $39.7M-41.4%
EPS (adj)

$0.31

Previous: $0.27+14.8%
Capital Expenditures

$2.8M

Previous: $611K+358.8%
Free Cash Flow

-$15M

Previous: -$3.21M-366.8%
Net Income

$13.8M

Previous: $0.00
Operating Income

$2.25M

Previous: $0.00
Gross Profit

$23.3M

Previous: $39.7M-41.4%
Cash & Equivalents

$233M

Previous: $0.00
Total Assets

$867M

Previous: $0.00
Stock-Based Comp

$2.42M

Previous: $825K+193.7%

Revenue & EPS history

Astrana Health · Revenue · Quarterly

$23.3M

Q4 2021-41.4%vs Q4 2020
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Forward guidance

ApolloMed anticipates full-year 2022 total revenue of between $1.03 billion and $1.08 billion, based on the Company’s existing business, current view of existing market conditions, and assumptions for the year ending December 31, 2022.

Tailwinds

  • Strong organic growth in core markets.
  • Participation in a Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation model.
  • Working closely with the Jade Health team and are on target to close by the end of the 2022 second quarter.
  • M&A pipeline remains robust.
  • Newly formed business development team in place.

Headwinds

  • Uncertainties related to its participation in a Centers for Medicare & Medicaid Services Innovation Center (“CMMI”) innovation model.
  • Ongoing investment in staff to support future growth.
  • Certain investments that depend on unpredictable macroeconomic factors.
  • Revenue guidance does not account for any potential acquisitions or other major business transactions.
  • Impact of the COVID-19 pandemic on the Company's business, operations and financial results.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

+0.7%

Avg return

Earnings day

-2.1%

Avg return

5 days after

+2.1%

Avg return

30 days after

40%

23 / 57 earnings

Positive

+83.3%

Q3 2011

Best reaction

-40.5%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+29.4%+22.5%+20.6%
Q3 2025-23.4%-29.4%-33.8%
Q1 2025-11.1%-20.8%-24.5%
Q4 2024-26.8%+5.0%+16.1%
Q3 2024-21.1%-27.9%-30.4%
Q2 2024-1.4%-1.8%+0.1%
Q1 2024-0.7%+1.5%+8.0%
Q4 2023+2.3%+1.8%-1.9%
Q3 2023+9.3%+2.9%+13.4%
Q2 2023+4.2%+3.5%-17.4%
Q1 2023+5.4%+7.0%-0.8%
Q4 2022+6.9%+5.2%+15.2%
Q3 2022+8.4%+8.9%-14.5%
Q2 2022-4.3%-11.0%-29.3%
Q1 2022-0.5%-5.4%-26.4%
Q4 2021-2.0%-11.0%-7.0%
Q3 2021+14.7%+30.5%+0.8%
Q2 2021-11.8%-10.7%-12.9%
Q1 2021+4.5%+4.7%+10.9%
Q4 2020+9.1%+8.8%+8.3%
Q3 2020-1.2%-1.6%+0.5%
Q2 2020+1.8%+2.4%+7.9%
Q1 2020-10.4%-11.6%+13.1%
Q4 2019-12.9%-24.0%+7.0%
Q3 2019-2.9%-0.9%+25.0%
Q2 2019-5.0%+4.8%+31.1%
Q1 2019-1.2%-4.3%-29.7%
Q4 2018-6.4%-8.3%-6.9%
Q3 2018+26.3%+4.0%-4.6%
Q2 2018-13.7%-23.3%-32.2%
Q4 2017+10.8%-6.3%+2.1%
Q1 2018+10.8%-6.3%+2.1%
Q3 2017+3.9%+3.9%+140.0%
Q2 2017+0.0%+0.0%-10.5%
Q1 2017+0.0%+6.7%+36.7%
Q1 2016+4.0%+4.0%+0.0%
Q3 2016-4.8%
Q2 2016-12.9%
Q1 2015-6.5%
Q3 2015-3.2%
Q2 2015+0.0%
Q2 2014+15.6%
Q4 2013
Q3 2013+1.6%
Q2 2013+13.5%
Q1 2013-13.3%
Q4 2012-2.2%
Q3 2012-9.1%
Q2 2012-40.5%
Q1 2012+0.0%
Q4 2011
Q3 2011+83.3%
Q2 2011+0.5%
Q1 2011-0.5%
Q4 2010-3.9%
Q3 2010+19.0%
Q2 2010+0.0%
Q1 2010-2.1%
Q4 2009+9.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro